|
Bangalore: Bangalore-based biotechnology company Biocon today said that the company has been featured amongst the top 25 global biotechnology companies in a report released by medical journal Med Ad News.  The report has evaluated drug-based firms, as these companies provide the best numbers to track the progress of the sector.
Companies have been ranked by revenue and by income, with Biocon Limited, ranked No 20, being the only Asian company to feature in this ranking.Nineteen of the top 25 companies are based in the US, while the others, apart from Biocon, are from Europe to Australia. Reacting to the listing, Kiran Mazumdar-Shaw, chairman and managing director, Biocon Limited said, "It is a matter of immense pride for Biocon to be ranked amongst the top global league of Biotech companies. This is a validation of our consistent effort at attaining global leadership and also highlights the true potential of this sector in a country like India. This industry will be a key driver in India's progress towards economic development." There are close to 5000 biotech companies across the globe. The top 25 biotech companies represent 62 percent of all biotech sales and probably over 90 percent of income. In November 2004, Biocon launched the world's first recombinant human insulin, Insugen, using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFRT in September 2006. Biocon's proprietary technologies have been used effectively in diabetology, oncology, cardiology, nephrology and other therapeutic treatments. The company's drug discovery pipeline offers novel therapies on a platform of affordable innovation. Acording to global industry summit BIO 2008, held in San Diego last month, the global biotechnology industry will be a $100-billion annual business by 2010. The actual revenues reached in 2007 were $85 billion. Biocon was established in 197, and with its two subsidiaries, Syngene and Clinigene, forms a fully integrated biotechnology enterprise, with specialised focus on biopharmaceuticals, contract research and clinical research, with several of its products having been acpted by the USFDA and Europe's EMEA. Strategic international acquisitions, such as acquiring a majority in the German pharmaceutical company, AxiCorp, have given Biocon wider global access and greater market penetration. | Leading Biotech Companies 2007 - By Revenue and Income | | Company/Country | 2007 Revenue (billions) | % Growth | 2007 Income (billions) | % Growth | | 1. Amgen (U.S.) | $14.8 | +4% | $3.2 | +7% | | 2. Genentech (U.S.) | $11.7 | +26% | $2.8 | +31% | | 3. UCB (Belgium) | $5.0 | +42% | $.2 | (56%) | | 4. Gilead Sciences (U.S.) | $4.2 | +40% | $1.6 | >999% | | 5. Genzyme (U.S.) | $3.8 | +20% | $.5 | >999% | | 6. Biogen Idec (U.S.) | $3.2 | +18% | $.6 | +193% | | 7. CSL ( Australia) | $2.8 | +14% | $.5 | +359% | | 8. Cephalon (U.S.) | $1.8 | +1% | ($.2) | (>999%) | | 9. Celgene (U.S.) | $1.4 | +56% | $.2 | +128% | | 10.Actelion (Switzerland) | $1.1 | +39% | $.1 | (49%) | | 11. Amylin Pharmaceuticals (U.S.) | $.8 | +53% | ($.2) | +3% | | 12. Elan (Ireland) | $.8 | +36% | ($.4) | (65%) | | 13. ImClone Systems (U.S.) | $.6 | (13%) | >$.1 | (>999%) | | 14. Millenium Pharmaceuticals (U.S.) | $.5 | +9% | >$.1 | NA | | 15. OSI Pharmaceuticals (U.S.) | $.3 | +41% | $.1 | >999% | | 16. Abraxis Bioscience (U.S.) | $.3 | +84% | (>$.1) | NA | | 17. Cubist Pharmaceuticals (U.S.) | $.3 | +51% | $.1 | >999% | | 18. Crucell (Netherlands) | $.3 | +55% | ($.1) | 100% | | 19. Nektar Therapeutics (U.S.) | $.3 | +25% | ($.1) | NA | | 20. Biocon (India) | $.3 | +10% | $.1 | +25% | | 21. PDL BioPharma (USA) | $.3 | +4% | - | NA | | 22. Alkermes (U.S.) | $.2 | +44% | - | +125% | | 23. United Therapeutics (U.S.) | $.2 | +32% | - | (73%) | | 24. ViroPharma (U.S.) | $.2 | +28% | $.1 | +42% | | 25. Vertex Pharmaceuticals (U.S.) | $.2 | (8%) | ($.4) | (100%) | | Top 25 | $52.5 | +13% | $8.7 | +129% | | Source: Med Ad News, June, 2008 |
|
